Cargando…

Administration of Intravenous Iron Formulations Induces Complement Activation in-vivo

Background: Intravenous (IV) iron is widely used to treat anemia in chronic kidney disease patients. Previously, iron formulations were shown to induce immune activation in-vitro. The current study aimed to investigate the effect of IV iron on complement activation in-vivo, and whether this subseque...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faria, Bernardo, Gaya da Costa, Mariana, Poppelaars, Felix, Franssen, Casper F. M., Pestana, Manuel, Berger, Stefan P., Daha, Mohamed R., Gaillard, Carlo A. J. M., Seelen, Marc A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712170/ https://www.ncbi.nlm.nih.gov/pubmed/31497011 http://dx.doi.org/10.3389/fimmu.2019.01885

Ejemplares similares

The Complement System in Dialysis: A Forgotten Story?
por: Poppelaars, Felix, et al.
Publicado: (2018)

Intradialytic Complement Activation Precedes the Development of Cardiovascular Events in Hemodialysis Patients
por: Poppelaars, Felix, et al.
Publicado: (2018)

Soluble CD59 in peritoneal dialysis: a potential biomarker for peritoneal membrane function
por: Faria, Bernardo, et al.
Publicado: (2020)

The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases?
por: Poppelaars, Felix, et al.
Publicado: (2021)

Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population
por: Gaya da Costa, Mariana, et al.
Publicado: (2018)

Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients
por: Poppelaars, Felix, et al.
Publicado: (2016)

Erratum to: Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients
por: Poppelaars, Felix, et al.
Publicado: (2016)

A functional TGFB1 polymorphism in the donor associates with long-term graft survival after kidney transplantation
por: Poppelaars, Felix, et al.
Publicado: (2021)

Tumor Necrosis Factor-α Gene Polymorphism is Associated with Short- and Long-Term Kidney Allograft Outcomes
por: Poppelaars, Felix, et al.
Publicado: (2022)

A non-muscle myosin heavy chain 9 genetic variant is associated with graft failure following kidney transplantation
por: Poppelaars, Felix, et al.
Publicado: (2023)

An interleukin 6‐based genetic risk score strengthened with interleukin 10 polymorphisms associated with long‐term kidney allograft outcomes
por: Eskandari, Siawosh K., et al.
Publicado: (2022)

Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantation
por: Poppelaars, Felix, et al.
Publicado: (2021)

Blocking Complement Factor B Activation Reduces Renal Injury and Inflammation in a Rat Brain Death Model
por: Jager, Neeltina M., et al.
Publicado: (2019)

Ferrous iron content of intravenous iron formulations
por: Gupta, Ajay, et al.
Publicado: (2016)

Iron infusion and newer intravenous iron formulations
por: Aung, Tim, et al.
Publicado: (2021)

Complement in glomerular injury
por: Berger, Stefan P., et al.
Publicado: (2007)

Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk
por: Ganz, Tomas, et al.
Publicado: (2020)

Complement Therapeutics in the Multi-Organ Donor: Do or Don't?
por: van Zanden, Judith E., et al.
Publicado: (2019)

Dysregulation of Complement Activation and Placental Dysfunction: A Potential Target to Treat Preeclampsia?
por: Pierik, E., et al.
Publicado: (2020)

Intravenous Iron Administration and Hypophosphatemia in Clinical Practice
por: Hardy, S., et al.
Publicado: (2015)

Severe hypophosphataemia after intravenous iron administration
por: Anand, Gurpreet, et al.
Publicado: (2017)

Complement, its role in innate immunity and autoimmunity
por: Daha, M
Publicado: (2003)

Recurrent severe hypophosphatemia following intravenous iron administration
por: Nataatmadja, Melissa Stephanie, et al.
Publicado: (2020)

Brain death‐induced lung injury is complement dependent, with a primary role for the classical/lectin pathway
por: van Zanden, Judith E., et al.
Publicado: (2020)

Comparative Evaluation of Nephrotoxicity and Management by Macrophages of Intravenous Pharmaceutical Iron Formulations
por: Connor, James R., et al.
Publicado: (2015)

Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis
por: Agüera, Maria Luisa, et al.
Publicado: (2015)

Role of complement in IgA nephropathy
por: Daha, Mohamed R., et al.
Publicado: (2015)

Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
por: Pai, AB, et al.
Publicado: (2017)

Bleomycin-Induced Lung Injury After Intravenous Iron Administration
por: Saccone, Nicole, et al.
Publicado: (2022)

Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
por: Hofman, Jesse M. G., et al.
Publicado: (2018)

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial‐IRON Trial
por: Núñez, Julio, et al.
Publicado: (2020)

Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney
por: Tiller, Gesa, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
por: Serpa, Priscila B. S., et al.
Publicado: (2018)

MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides
por: Talsma, Ditmer T., et al.
Publicado: (2020)

A case of intravenous iron administration resulting in cerebral edema expansion
por: Espinosa, Jonathan, et al.
Publicado: (2023)

Intravenous Iron Therapy: Re-administration after Prior Adverse Reaction
por: Aung, Tim, et al.
Publicado: (2023)

Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions
por: Arastu, Asad H., et al.
Publicado: (2022)

Hypersensitivity to Intravenous Iron Preparations
por: Caimmi, Silvia, et al.
Publicado: (2022)

Risk of Infection Associated With Administration of Intravenous Iron: A Systematic Review and Meta-analysis
por: Shah, Akshay A., et al.
Publicado: (2021)

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
por: Macdougall, Iain C., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kqfibgfa710qm2aj21ouh5uin1